Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pressure Mounts For Agreement On New UK Voluntary Pricing Scheme

Executive Summary

With the clock ticking on UK drug pricing negotiations, it is still unclear whether even high-level terms of a new voluntary deal will be agreed in time.

You may also be interested in...



Voluntary Vs Statutory: Pharma Firms Soon To Choose Between Two UK Pricing Schemes

The UK’s new voluntary drug pricing and access deal is a “paradigm shift” that will see companies paying different levels of rebates depending on their product mix, with higher payments on older medicines making headroom for growth in newer drugs, according to one lawyer.

UK Announces New Five-Year Voluntary Drug Pricing Deal

The VPAG includes a gradual rise in allowable branded medicine sales to the NHS and differentiated payment mechanisms for older and newer products. Industry will also commit to invest £400m in “pioneering” clinical trials, innovative manufacturing, and novel approaches to health technology assessments.

UK Govt Under Fire From Pharma Industry Over Statutory Pricing Scheme Changes

The UK’s pharmaceutical industry association, the ABPI, claims that “fundamental failures” in the government’s consultation and impact assessment for proposed changes to the branded medicines statutory pricing scheme could be grounds for legal challenge.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel